Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13393905 | 0.91 | ADORA2A (0.53) | ADORA2AADORA1ADORA3 | |
| SCHEMBL13424728 | 0.88 | ADORA2A (0.48) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3308724 | 0.87 | ADORA2A (0.62) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3307628 | 0.84 | ADORA2A (0.63) | ADORA2AADORA1ADORA3MEN1LMNA | |
| SCHEMBL13393931 | 0.83 | ADORA2A (0.55) | ADORA2AADORA1ADORA3 | |
| Hydrochloric Acid SCHEMBL3303861 | 0.83 | ADORA2A (0.54) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3300111 | 0.79 | ADORA2A (0.55) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3303905 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1ADORA3MEN1USP2 | |
| SCHEMBL3303639 | 0.79 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL13393914 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010045017-A1 | AMINES AND SULFOXIDES OF THIENO [2,3-D] PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093764-A1 | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093764-A1 | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093764-A1 | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093764-A1 | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 4/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.